香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 佈 全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 WAI YUEN TONG MEDICINE HOLDINGS LIMITED * 僅供識別 – 1 – 業 績 Wai Yuen Tong Medicine Holdings Limited（位 元 堂 藥 業 控 股 有 限 公 司*）（「本公司」）董 事 會（「董事會」或「董 事」）欣然公佈本公司及其附屬公司（統 稱「本集團」）截至二 零 二 五 年 三 月 三 十 一 日 止 年 度 之 綜 合 業 績，連 同 上 個 財 政 年 度 之 比 較 數 字 載 列 如 下： 綜合損益及其他全面收益表 （位 元 堂 藥 業 控 股 有 限 公 司*） （於 百 慕 達 註 冊 成 立 之 有 限 公 司） （股 份 代 號：897） 截至二零二五年三月三十一日止年度之 全年業績公佈 | 年度財務摘要 | | | | | --- | --- | ...

Financial Performance - The Group's gross profit decreased by approximately HK$4.2 million or approximately 2.3% to approximately HK$182.0 million for the Period compared to approximately HK$186.2 million for the six months ended 30 September 2023[8]. - Revenue for the six months ended September 30, 2024, was HK$346,843,000, a decrease of 5.4% from HK$368,326,000 in the same period of 2023[126]. - Profit attributable to owners of the parent increased to approximately HK$23.7 million, up from approximately HK$3.5 million for the same period last year, mainly due to fair value gains on investment properties and decreased impairment losses[29]. - Profit before tax from continuing operations increased to HK$25,152,000, up 91.1% from HK$13,129,000 in the previous year[126]. - Profit for the period from continuing operations was HK$23,742,000, compared to HK$12,529,000 in the prior year, representing a growth of 89.0%[126]. - The company reported a profit attributable to owners of the parent of HK$23,701,000 for the six months ended September 30, 2024, compared to HK$3,549,000 in the same period of 2023, representing a significant increase[154]. - Total comprehensive income for the period was HK$24,004,000, a recovery from a loss of HK$189,922,000 in the previous year[154]. - Basic and diluted earnings per share attributable to ordinary equity holders of the parent for the period was HK2.10 cents, up from HK0.30 cent in the prior year[154]. - The company experienced a total comprehensive loss of HK$211,046,000 in the previous period, indicating a substantial turnaround in performance[153]. Expenses and Costs - Selling and distribution expenses increased by approximately HK$20.0 million or approximately 17.9% to approximately HK$131.9 million, primarily due to increased marketing costs for new product launches and e-commerce expansion[25]. - Administrative expenses rose by approximately HK$8.3 million or approximately 15.1% to approximately HK$63.4 million, mainly due to higher legal and professional fees[28]. - Administrative expenses increased to HK$63,443,000, up 15.1% from HK$55,117,000[126]. Assets and Liabilities - The current ratio was approximately 1.5, down from approximately 2.2 as of 31 March 2024, indicating a tightening liquidity position[17]. - As at 30 September 2024, the Group's total cash and cash equivalents were approximately HK$96.3 million, a decrease from approximately HK$159.4 million as of 31 March 2024[37]. - Total non-current assets decreased from HK$ 1,264,882,000 to HK$ 1,217,055,000, a decline of approximately 3.75%[155]. - Current liabilities decreased from HK$ 380,872,000 to HK$ 359,530,000, a reduction of about 5.6%[156]. - Net current assets decreased significantly from HK$ 449,356,000 to HK$ 197,500,000, representing a decline of approximately 56.0%[156]. - Total assets less current liabilities decreased from HK$ 1,714,238,000 to HK$ 1,414,555,000, a decrease of around 17.5%[156]. - Total equity decreased from HK$ 1,385,456,000 to HK$ 1,198,517,000, reflecting a decline of about 13.5%[156]. - Cash and cash equivalents decreased from HK$ 763,400,000 to HK$ 557,030,000, a drop of approximately 26.9%[155]. - Trade receivables increased from HK$ 81,356,000 to HK$ 86,457,000, an increase of about 6.4%[155]. - Interest-bearing bank borrowings increased slightly from HK$ 184,749,000 to HK$ 185,386,000, an increase of approximately 0.3%[156]. - Financial assets at fair value through profit or loss decreased from HK$ 28,753,000 to HK$ 12,258,000, a decline of about 57.4%[155]. - Total non-current liabilities decreased from HK$ 328,782,000 to HK$ 216,038,000, a reduction of approximately 34.2%[156]. Investments and Commitments - As of September 30, 2024, the Group had capital commitments of approximately HK$12,800,000 for the acquisition of properties, plants, and equipment, an increase from approximately HK$2,600,000 as of March 31, 2024[44]. - The Group provided a guarantee to a bank for a maximum financing of HK$370,000,000 related to agricultural products in China, unchanged from March 31, 2024[45]. - As of September 30, 2024, there were no significant investments, acquisitions, or disposals of subsidiaries, associates, or joint ventures during the period[46]. Market and Strategic Positioning - The Group continues to develop new products, including "Madame Pearl's" cough syrup and "Pearl's" mosquito products, to meet consumer demand in both Hong Kong and Mainland China[33]. - The Group has engaged local distributors to enhance market penetration of its products in Mainland China, particularly in medical and consumer channels[13]. - The Group is strategically positioned to capitalize on favorable national policies in the Guangdong-Hong Kong-Macao Greater Bay Area, presenting significant growth and expansion opportunities in the Chinese medicine and health food industry[48]. - The national policy for the Guangdong-Hong Kong-Macau Greater Bay Area presents substantial growth opportunities for the Chinese pharmaceutical and health food sectors, which the company aims to leverage[75]. - The company is committed to investing in cross-border e-commerce initiatives to enhance brand presence and capitalize on regional opportunities[75]. - The company is strategically positioned to align its business strategies with the evolving market dynamics of the Greater Bay Area[75]. Corporate Governance - The company has maintained compliance with the Corporate Governance Code, except for a deviation where the roles of chairman and managing director are held by the same individual[96]. - The company plans to continue reviewing its corporate governance practices to enhance the best interest of the Group as a whole[99]. - The company is focused on maintaining high standards of corporate governance, emphasizing transparency, accountability, and integrity[97]. - The company has established an Audit Committee to oversee financial reporting processes and risk management, comprising three independent non-executive directors[136]. - The Audit Committee has reviewed the unaudited interim condensed consolidated financial information for the six months ended September 30, 2024, ensuring compliance with financial reporting standards[136]. - The company has adopted a code of conduct for securities transactions by directors, confirming compliance with the required standards throughout the period[134]. Share Capital and Options - The total number of share options available for grant as of September 30, 2024, was 117,110,288, with no share options granted, exercised, canceled, or lapsed under the 2023 Scheme during the period[70]. - The company did not grant, exercise, or cancel any share options under the 2023 Scheme during the period, with a total of 117,110,288 options available for grant as of September 30, 2024[94]. - The company plans to refresh the Scheme Mandate Limit for share options, which currently stands at 10% of shares in issue[105]. - The 2023 Share Option Scheme is effective for a period of ten years starting from August 22, 2023[108]. - The company repurchased a total of 46,000,000 shares at HK$0.01 each, which were subsequently cancelled on May 3, 2024[103]. - The total number of shares repurchased during the period was 46,000,000 at an average price of HK$0.260, totaling HK$11.80 million[113]. - As of September 30, 2024, the total number of shares in issue was 1,125,102,888[116]. - The company has issued a total of 1,125,102,888 shares as of the report date, reflecting its capital structure[133]. - The company aims to enhance shareholder value through share repurchases authorized at the annual general meeting held on August 22, 2023[133]. Foreign Exchange and Risks - The Group faced foreign exchange risks primarily due to its operations in mainland China, resulting in a retranslation loss of approximately HK$100,000 as of September 30, 2024, compared to a loss of approximately HK$187,500,000 for the six months ended September 30, 2023[43]. Subsequent Events - There were no material subsequent events undertaken by the Company or the Group after September 30, 2024, up to the date of this report[72].

Financial Performance - Revenue for the six months ended September 30, 2024, was HKD 346.8 million, a decrease of 5.8% compared to HKD 368.3 million in the same period of 2023[1]. - Gross profit for the same period was HKD 182.0 million, down 2.3% from HKD 186.2 million year-on-year[1]. - Profit attributable to equity holders of the parent was HKD 23.7 million, representing a significant increase of 577.1% from HKD 3.5 million in the previous year[1]. - Basic and diluted earnings per share increased to HKD 2.10 from HKD 0.30, reflecting a growth of 577.1%[1]. - The company reported a net profit of HKD 23,742,000 for the period, compared to HKD 21,124,000 in the previous year, marking an increase of approximately 12.4%[38]. - The operating profit before tax was HKD 25,152,000, a decrease from HKD 38,429,000, representing a decline of about 34.5%[38]. - Total revenue for the six months ended September 30, 2024, decreased by approximately HKD 21,500,000 to about HKD 346,800,000, primarily due to weaker sales in traditional Chinese medicine and health food[82]. - Gross profit for the same period decreased by approximately HKD 4,200,000 or about 2.3% to approximately HKD 182,000,000, mainly due to reduced sales in traditional Chinese medicine and health food[83]. Assets and Liabilities - Net asset value as of September 30, 2024, was HKD 1,198.5 million, down 13.5% from HKD 1,385.5 million as of March 31, 2024[1]. - Cash and cash equivalents decreased to HKD 96.3 million, a decline of 37.9% from HKD 155.0 million[1]. - Total current liabilities decreased from HKD 380,872,000 to HKD 359,530,000, a reduction of approximately 5.5%[18]. - Net current assets dropped significantly from HKD 449,356,000 to HKD 197,500,000, representing a decline of about 56.0%[19]. - Total assets minus current liabilities decreased from HKD 1,714,238,000 to HKD 1,414,555,000, a decrease of approximately 17.5%[20]. - Total non-current liabilities decreased from HKD 328,782,000 to HKD 216,038,000, a reduction of about 34.2%[22]. - Total equity decreased from HKD 1,385,456,000 to HKD 1,198,517,000, reflecting a decline of approximately 13.5%[26]. - Trade receivables as of September 30, 2024, amounted to HKD 86,457,000, an increase from HKD 81,356,000 as of March 31, 2024[75]. - Trade payables as of September 30, 2024, decreased to HKD 19,940,000 from HKD 30,907,000 as of March 31, 2024[79]. Market and Segment Performance - The company operates in three main segments: Traditional Chinese Medicine, Western Medicine, and Property Investment[33]. - Revenue from customer contracts amounted to HKD 344,812,000, down from HKD 366,721,000 year-over-year, indicating a decrease of about 6.0%[41]. - The Chinese market contributed HKD 41,083,000 to total revenue, compared to HKD 36,636,000 in the previous year, reflecting an increase of approximately 12.0%[41]. - The Hong Kong market generated HKD 272,861,000 in revenue, down from HKD 295,023,000, which is a decline of around 7.5%[43]. - Sales of traditional Chinese medicine in Hong Kong decreased by 16.5% during the period from April to September 2024 compared to the same period in 2023[90]. - The flagship brand "Pei Fu Ren" achieved a revenue growth of 5.8% year-on-year, driven by strategic sales and marketing activities, maintaining its position as the top-selling cough syrup in Hong Kong for 14 consecutive years[96]. Expenses and Costs - Other income and gains decreased significantly to HKD 46.2 million from HKD 69.6 million year-on-year[4]. - Sales and distribution expenses increased by approximately HKD 20,000,000 or about 17.9% to approximately HKD 131,900,000, mainly due to increased marketing costs associated with new product launches and e-commerce business expansion[85]. - Administrative expenses increased by approximately HKD 8,300,000 or about 15.1% to approximately HKD 63,400,000, primarily due to higher legal and professional fees[86]. - The cost of inventories recognized as an expense, including obsolete inventory provision, was HKD 164,824,000 for the six months ended September 30, 2024, compared to HKD 182,114,000 in 2023, a decrease of approximately 9.5%[51]. - The depreciation of owned assets for the six months ended September 30, 2024, was HKD 16,915,000, down from HKD 18,775,000 in 2023, reflecting a decline of about 9.8%[52]. Strategic Initiatives - The company plans to focus on expanding its market presence and enhancing product offerings in the upcoming periods[4]. - The company plans to expand its market presence in mainland China, focusing on increasing sales in the healthcare sector[41]. - The company is actively pursuing new product development and technological advancements to enhance its competitive edge in the market[41]. - The company is actively expanding cross-border e-commerce channels, resulting in over 2x growth in cross-border e-commerce sales compared to the same period last year[91]. - The company is focusing on the health product market and plans to launch four innovative products next year targeting specific areas: (i) blood sugar levels, (ii) cholesterol levels, (iii) liver health, and (iv) joint function[117]. - The group is committed to investing in cross-border e-commerce initiatives to enhance brand influence and seize regional opportunities[113]. Governance and Compliance - The company emphasizes high standards of corporate governance, focusing on transparency, accountability, integrity, and independence to enhance competitiveness and operational efficiency[122]. - The audit committee, consisting of three independent non-executive directors, has reviewed the unaudited condensed consolidated financial statements for the six months ending September 30, 2024[126]. - The mid-term financial results have been published on the Hong Kong Stock Exchange website and the company's website, complying with all regulatory requirements[127].

Financial Performance - For the fiscal year ending March 31, 2024, the company reported revenue of HKD 783.9 million, an increase of 8.3% compared to HKD 723.6 million in the previous fiscal year[2]. - Gross profit for the same period was HKD 394.8 million, reflecting a 15.3% increase from HKD 342.4 million year-on-year[2]. - Core profit from continuing operations surged by 53.9% to HKD 62.5 million, up from HKD 40.6 million in the prior year[2]. - The company recorded a net profit of HKD 4.0 million, a 21.2% increase from HKD 3.3 million in the previous fiscal year[2]. - The company reported a revenue of HKD 553,973,000 for the year ending March 31, 2024, a decrease of 1.5% from HKD 562,830,000 in the previous year[71]. - Total revenue amounted to HKD 1,337,854,000, an increase from HKD 1,286,428,000 year-over-year, representing a growth of 4%[85]. - Revenue from customer contracts reached HKD 779,398,000 for continuing operations, compared to HKD 717,550,000 in the previous year, reflecting a growth of 8.6%[85]. - The adjusted pre-tax loss for the year was HKD 584,000, compared to a pre-tax loss of HKD 12,667,000 in the previous year, indicating an improvement[89]. - The company reported a loss attributable to equity holders of approximately HKD 15,400,000, an improvement from a loss of HKD 20,500,000 in the previous year[80]. Assets and Liabilities - The net asset value decreased significantly by 62.4% to HKD 1,385.5 million from HKD 3,688.4 million[2]. - Cash and cash equivalents dropped by 70.5% to HKD 155.0 million, down from HKD 525.9 million[2]. - The net current assets decreased to HKD 449,356,000 in 2024 from HKD 1,045,182,000 in 2023, representing a decline of approximately 57.0%[18]. - Total assets less current liabilities dropped to HKD 1,714,238,000 in 2024 from HKD 5,356,627,000 in 2023, a decrease of about 68.0%[18]. - Total non-current liabilities decreased to HKD 328,782,000 in 2024 from HKD 1,668,243,000 in 2023, reflecting a reduction of approximately 80.3%[18]. - The group’s investment in bonds and equity securities had a fair value of approximately HKD 33,100,000 as of March 31, 2024, down from approximately HKD 193,700,000 in 2023[151]. - As of March 31, 2024, the group's bank loans and notes payable amounted to approximately HKD 438.1 million, a decrease from HKD 3,086.8 million in 2023[156]. Dividends and Shareholder Returns - The company proposed a final cash dividend of HKD 3.0 per share, with a special dividend of HKD 14.7 per share[2]. - The company proposed a final cash dividend of HKD 3.0 cents per share, totaling HKD 33,753,000, and a special dividend of HKD 14.7 cents per share, totaling HKD 165,390,000[67]. - A special dividend was approved, involving the distribution of shares in two subsidiaries to eligible shareholders, based on their respective holdings[93]. Corporate Governance and Compliance - The company has established an audit committee composed of independent non-executive directors to oversee financial reporting and compliance[26]. - The company has adopted the principles of corporate governance as per the Stock Exchange Listing Rules, with some deviations noted[21]. - The company plans to continue reviewing and suggesting improvements regarding its corporate governance practices[22]. - The financial statements have been prepared in accordance with Hong Kong Financial Reporting Standards, with no significant impact from recent amendments on the classification of liabilities[39]. Operational Developments - The company plans to continue expanding its market presence and investing in new product development to drive future growth[4]. - The group has four reportable operating segments, including the production and sale of traditional Chinese medicine and health food products, primarily in mainland China and Hong Kong[55]. - The group has classified the management and sales of agricultural product trading market properties as discontinued operations following the completion of a physical distribution[56]. - The group has launched new products targeting respiratory health, including "Wild Cordyceps King," aimed at enhancing respiratory function for both adults and children[109]. - The flagship brand "Pei Fu Ren" has maintained its position as the top-selling cough syrup in Hong Kong for 14 consecutive years[111]. - The group has strengthened its online sales channels, expanding its e-commerce presence through its own platform and selected third-party platforms[111]. - The group plans to continue developing new products in both Hong Kong and mainland China markets to expand distribution networks for its brands[111]. Financial Management - The debt-to-asset ratio improved to 21.7%, down from 46.3% in the previous year, indicating a stronger balance sheet[2]. - The current ratio improved to approximately 2.2 from 1.6 in 2023, indicating better short-term financial health[175]. - The group maintains a cautious financial management policy, with a debt-to-equity ratio of approximately 21.7%, down from 46.3% in 2023[175]. - The group is actively monitoring market changes and adjusting its investment portfolio to ensure stable income generation[176]. Employee and Operational Costs - Employee benefits expenses totaled HKD 231,393,000, up from HKD 144,286,000, showing a significant increase of 60.5%[89]. - Research and development costs were HKD 1,786,000, slightly down from HKD 1,897,000 in the previous year[89]. Market Outlook - The company anticipates a moderate economic growth in Hong Kong, with GDP expected to grow by 2.7% year-on-year[107].

智通财经APP数据显示，截止3月11日收盘，有78只股票创52周新高，其中位元堂(00897)、乐思集团(02540)、博雅互动(00434)创高率位于前3位，分别为198.85%、65.00%、30.64%。另外有54只股票创52周新低，其中中国供应链产业(03708)、呷哺呷哺(00520)、朸濬国际(01355)创低率位于前三位，分别为-41.86%、-13.45%、-10.71%。 52周新高排行 股票名称 收盘价 最高价 创高率 位元堂(00897) 0.226 0.260 198.85% 乐思集团(02540) 2.500 2.640 65.00% 博雅互动(00434) 2.260 2.260 30.64% 光尚文化控股(08082) 0.041 0.042 13.51% 中电华大科技(00085) 1.790 1.840 10.84% 长久股份(06959) 24.500 24.450 10.63% 怡俊集团控股(02442) 1.960 2.360 9.77% TS WONDERS(01767) 0.220 0.220 8.91% 华营建筑(0158 ...

Revenue and Profit Performance - Revenue for the six months ended 30 September 2023 increased to HK$678,804,000, up from HK$606,127,000 in the same period last year, representing a growth of approximately 12%[18] - Gross profit for the period was HK$324,027,000, compared to HK$268,189,000 in the previous year, reflecting a 20.8% increase[18] - Profit before tax for the six months ended 30 September 2023 was HK$38,429,000, a significant improvement from a loss of HK$19,023,000 in the same period last year[18] - Profit attributable to owners of the parent was HK$3.549 million, a turnaround from a loss of HK$53.385 million in the previous year[25] - Basic and diluted earnings per share attributable to ordinary equity holders of the parent were HK0.30 cents, compared to a loss of HK4.35 cents in the same period last year[26] - Revenue for the period reached 2,097,109 units[156] - Profit for the period was 3,549 units[170] Share Repurchase and Issuance - The company repurchased 33,540,000 shares at a total cost of HK$14,727,600 during July 2023, with the highest purchase price per share at HK$0.45 and the lowest at HK$0.425[10] - The total number of shares in issue as of 30 September 2023 was 1,171,102,888[10] - Rich Time, WOE, and Wang On each hold 810,322,940 shares, representing 69.19% of the company's shares[34] - Mr. Tang holds a 50.67% interest in Wang On, which indirectly owns Rich Time and WOE, both holding 810,322,940 shares in the company[36] - Mr. Tang Ching Ho holds 7,320,095,747 shares in CAP, representing approximately 73.54% of CAP's total issued share capital[87] - Mr. Tang Ching Ho is also interested in 810,322,940 shares of the Company held by Rich Time Strategy Limited, with an approximate 50.67% interest[88] Share Option Schemes - The 2013 Share Option Scheme expired on 21 August 2023, and a new 2023 Share Option Scheme was adopted on 22 August 2023, effective for 10 years[40] - The 2023 Share Option Scheme allows the company to grant options to employees, directors, and associates as incentives, with a maximum issuance limit of 10% of the company's issued shares[40] - Any grant of options resulting in shares issued or to be issued exceeding 1% of the company's total shares within a 12-month period requires separate shareholder approval, with the participant and close associates abstaining from voting[42] - Share options granted to directors, chief executives, or substantial shareholders must be approved by independent non-executive directors (INEDs), excluding any INED who is the grantee[42] - Grants to substantial shareholders or INEDs resulting in shares exceeding 0.1% of the company's total shares within 12 months require shareholder approval via a poll, with the grantee and associates abstaining from voting[42] - The exercise period for options is determined by the Board but must not exceed 10 years from the grant date[42] - The minimum holding period before options can be exercised is generally not less than 12 months, with a vesting period that may be shortened under certain circumstances to encourage exceptional performance[42] - The 2023 Share Option Scheme is valid for 10 years starting from August 22, 2023, with no further options to be granted after this period, though existing options remain exercisable[42] - The exercise price for options must not be less than the highest of: (i) the closing price on the grant date, (ii) the average closing price for the 5 business days preceding the grant date, or (iii) the nominal value of the company's shares[42] - No share options were granted, exercised, cancelled, or lapsed under the 2013 and 2023 Schemes during the period, with 117,110,288 share options available for grant as of 30 September 2023[45] - The CAP 2022 Scheme, effective from 26 August 2022, allows the CAP Board to grant share options to eligible participants, with a validity period of 10 years until 25 August 2032[45] - The number of share options granted to any CAP Participant in any 12-month period cannot exceed 1% of the issued CAP Shares without prior shareholder approval[48] - Share options granted to substantial shareholders or independent non-executive directors exceeding 0.1% of issued CAP Shares and HK$5,000,000 in value require prior shareholder approval[48] - The CAP Board may refresh the share option limit to 10% of the total issued CAP Shares, subject to shareholder approval, with a cap of 30% for all outstanding options[49] - As of 30 September 2023, 50,000,000 share options were outstanding for CAP Director Leung Sui Wah, Raymond, with an exercise price of HK$0.118 per share[53] - Other employees had 126,000,000 share options outstanding as of 30 September 2023, down from 161,000,000 due to 35,000,000 lapsed options[53] - The total outstanding share options under the CAP 2012 Scheme decreased from 211,000,000 to 176,000,000 during the period, primarily due to lapsed options[53] - 35,000,000 share options lapsed under the CAP 2012 Scheme, leaving 176,000,000 shares available for issue, representing approximately 1.77% of the existing issued share capital of CAP[56] - No share options were granted, exercised, canceled, or lapsed under the CAP 2022 Scheme, with 995,306,782 share options remaining available for grant as of 30 September 2023[56] Asset and Liability Changes - Total non-current assets decreased to HK$4.057 billion from HK$4.311 billion as of 31 March 2023[27] - Total current assets decreased to HK$2.526 billion from HK$2.702 billion as of 31 March 2023[27] - Net current assets were HK$910.085 million, down from HK$1.045 billion as of 31 March 2023[27] - Trade receivables decreased to HK$66.566 million from HK$68.028 million as of 31 March 2023[27] - Cash and cash equivalents decreased to HK$456 million from HK$525.869 million as of 31 March 2023[27] - Trade payables increased to HK$125.164 million from HK$79.489 million as of 31 March 2023[27] - Other payables and accruals decreased to HK$640.713 million from HK$690.388 million as of 31 March 2023[27] - Total assets less current liabilities decreased from HK$5,356,627,000 to HK$4,968,002,000 as of 30 September 2023[62] - Non-current liabilities decreased from HK$1,668,243,000 to HK$1,482,266,000, primarily due to reductions in unsecured notes and interest-bearing bank borrowings[62] - Net assets decreased from HK$3,688,384,000 to HK$3,485,736,000, with equity attributable to owners of the parent declining from HK$2,349,191,000 to HK$2,225,827,000[62] - Total assets amounted to 2,349,191 units[166] Comprehensive Loss and Other Financial Metrics - Total comprehensive loss for the period was HK$189.922 million, compared to HK$420.356 million in the same period last year, showing a significant improvement[22][25] - Net loss for the period was (27,150) units[157] - Other comprehensive loss for the period was (10,076) units[185] - Changes in fair value resulted in a loss of (23,420) units[186] - Reversal of impairment losses on financial assets was (13,344) units[191] - Reclassification adjustment for gains/losses included in profit or loss was (93) units[200] Corporate Governance - The Company deviated from code provision C.2.1 of the Corporate Governance Code, with Mr. Tang Ching Ho serving as both chairman and managing director[59] - The Company maintains a high standard of corporate governance, emphasizing transparency, accountability, integrity, and independence[60] - The Board comprises three executive Directors and four independent non-executive Directors, ensuring a balance of skills and experience for the Group's development[59]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部分內容而產生或 因倚賴該等內容而引致之任何損失承擔任何責任。 WAI YUEN TONG MEDICINE HOLDINGS LIMITED （位 元 堂 藥 業 控 股 有 限公 司 *） （於百慕達註冊成立之有限公司） （股份代號：897） 截至二零二三年九月三十日止六個月之中期業績公佈 中期財務摘要 截至九月三十日止六個月 二零二三年 二零二二年 變動 百萬港元 （未經審核） （未經審核） 收益 678.8 606.1 12.0% 毛利 324.0 268.2 20.8% 母公司擁有人應佔溢利╱（虧損） 3.5 (53.4) 106.6% 每股盈利╱（虧損）（港仙） — 基本及攤薄 0.30 (4.35) 4.65 於 於 二零二三年 二零二三年 ...

Sales Performance and Market Position - Wai Yuen Tong has maintained its position as the top-selling product in the cough remedy category for nine consecutive years, based on sales value and volume in Hong Kong[14]. - Wai Yuen Tong's Hou Tsao Powder has been recognized for its sales performance, reinforcing the brand's market leadership[14]. - The flagship products include "Angong Niuhuang Wan" series, "Young Yum Pill," and "Hou Tsao Powder," with the latter ranked first in sales for 9 consecutive years in Hong Kong[28]. - The Group's flagship brand "Madame Pearl's" achieved the Hong Kong cough syrup sales champion for 12 consecutive years, supported by strategic sales and marketing efforts[58]. - The revenue of "Pearl's" Mosquitout product range reported satisfactory growth over the previous year, establishing leadership in the mosquito repellent product category in Hong Kong[59]. Commitment to Traditional Chinese Medicine (TCM) - The company reported a commitment to promoting Traditional Chinese Medicine (TCM) globally, emphasizing the importance of TCM in socio-economic development and healthcare services[22]. - The State Council of China has outlined future development priorities for TCM, indicating strong governmental support for the industry[22]. - Wai Yuen Tong aims to establish higher quality standards in the TCM industry while providing comprehensive pharmaceutical products and services[23]. - The company continues to focus on the integration of traditional practices with modern healthcare needs, aligning with national health policies[22]. - The company is positioned to leverage the growing demand for TCM services due to an aging population and the booming healthcare services industry in China[22]. Financial Performance - Total revenue for the financial year ended March 31, 2023, decreased by approximately 7.5% to approximately HK$1,286.4 million, primarily due to a decrease in property sales in agricultural produce exchange markets[46]. - The Group recorded a loss attributable to owners of the parent of approximately HK$20.5 million, a significant reduction from a loss of approximately HK$108.9 million in the previous year[47]. - Revenue from Chinese pharmaceutical and health food products increased to approximately HK$635.0 million, representing a growth of approximately 23.9% from the previous year[56]. - The total revenue of traditional Chinese medicine and health food products increased to approximately HK$635 million, representing a growth of about 23.9% compared to the previous year[60]. - The total revenue of Western pharmaceutical and health food products grew by 100.1% over the same period last year[64]. Business Expansion and Operations - As of March 31, 2023, the Group operated over 100 stores across Mainland China, Hong Kong, and Macau, with more than 80 Chinese medicine practitioners in Hong Kong[28]. - During the review year, the Group opened 9 new stores in Hong Kong and Macau, particularly in residential districts, indicating a growing demand for Chinese medicine clinic services[27]. - The Group launched new products across five major categories of Chinese medicine, enhancing product diversity and selection[28]. - The Group's business model leverages franchised stores for rapid expansion in the Chinese medicine sector[28]. - The Group has actively developed e-commerce business channels, distributing products through its own online platform and selected third-party platforms[63]. Legal Matters and Corporate Governance - The group continues to be the legal and beneficial owner of Baisazhou Agricultural, as confirmed by multiple court rulings[149][156]. - On April 20, 2023, the court ruled that Ms. Wang and Tian Jiu must pay damages to the group amounting to HK$567,037,325.74, plus interest from January 18, 2021[157]. - The group has been involved in multiple civil litigations since 2011 related to the Baisazhou acquisition, with various court decisions upholding its ownership[144][153]. - The Supreme People's Court dismissed the appeal from Ms. Wang and Tian Jiu regarding the December 23, 2019 judgment, reaffirming the group's ownership[153][158]. - The group has faced allegations of forged documentation related to the Baisazhou acquisition, which have been dismissed by the courts[145][152]. Sustainability and Corporate Social Responsibility - The company has received recognition as a "Caring Company" for over 10 years, reflecting its commitment to social responsibility[15]. - The Group's commitment to sustainability includes the installation of solar panels at the Yuen Long Factory to reduce carbon emissions[32]. - The Group's agricultural produce exchange markets have maintained health and hygiene measures to adapt to the post-pandemic environment[189]. Management and Employee Relations - CAP employed 1,941 staff as of March 31, 2023, an increase from 1,872 in 2022, with approximately 35.4% located in Hong Kong and Macau[172]. - The company provides various employee benefits, including medical and retirement benefits, and structured training programs[172]. - CAP recognizes employees as key contributors to its success and strives to provide a safe workplace[172]. - CAP has adopted a share option scheme in August 2022 to incentivize eligible participants and enhance the company's value[172]. Market Outlook and Strategic Initiatives - The expected faster growth of Mainland China's economy and the lifting of cross-boundary restrictions are anticipated to support Hong Kong's exports[182]. - Wai Yuen Tong aims to increase market share by opening self-operated and franchised retail outlets in the PRC, Hong Kong, and Macau[183]. - The CAP Group plans to build a nationwide agricultural produce exchange network leveraging its industry-leading position and advanced management systems[184]. - The Central Government of China has prioritized agricultural development, promoting investments in agricultural produce markets and improving logistics infrastructure[190]. - The CAP Group is adopting an "asset light" strategy to expand operations in the PRC and is exploring online platform development to leverage technology advancements[191].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負 責，對其準確性或完整性亦不發表聲明，並明確表示，概不就因本公佈全部或任 何部分內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 WAI YUEN TONG MEDICINE HOLDINGS LIMITED ( 位 元 堂 藥 業 控 股 有 限 公 司 *) （於百慕達註冊成立之有限公司） （股份代號：897） 截至二零二三年三月三十一日止年度之 全年業績公佈 年度財務摘要 百萬港元 二零二三年 二零二二年 財政年度 財政年度 按年變動 收益 1,286.4 1,391.4 (7.5)% 毛利 611.8 570.4 7.3% 母公司擁有人應佔虧損 (20.5) (108.9) 81.2% 每股虧損（港仙） – 基本及攤薄 (1.69) (8.84) 7.15 於二零二三年 於二零二二年 ...

Financial Performance - For the six months ended September 30, 2022, total revenue decreased by approximately 7.6% to approximately HK$606.1 million, primarily due to decreased sales performance in the management and sale of properties in agricultural produce exchange markets[15]. - The Group recorded a loss attributable to owners of the parent amounting to approximately HK$53.4 million, compared to a profit of approximately HK$14.1 million for the same period in 2021[16]. - The loss was mainly due to a decrease in fair value gains on investment properties, impairment losses on property, plant and equipment, and a decrease in revenue from property sales in agricultural produce exchange markets in the PRC[16]. - Revenue for the six months ended 30 September 2022 was HK$606,127,000, a decrease from HK$656,082,000 in the same period of 2021, representing a decline of approximately 7.6%[180]. - Gross profit for the same period was HK$268,189,000, down from HK$275,213,000, reflecting a decrease of about 2.4%[180]. - The Company reported a loss before tax of HK$19,023,000 for the six months ended 30 September 2022, compared to a profit of HK$54,289,000 in the prior year[180]. - The profit for the period was a loss of HK$35,643,000, contrasting with a profit of HK$35,320,000 in the same period of 2021[180]. - The company reported a total comprehensive loss attributable to owners of the parent of HK$239,983,000 for the six months ended September 30, 2022, compared to a comprehensive income of HK$81,851,000 in the same period of 2021[187]. - The profit attributable to owners of the parent was a loss of HK$53,385,000 for the six months ended September 30, 2022, compared to a profit of HK$14,109,000 in the same period of 2021[187]. Revenue Sources - The revenue of Chinese pharmaceutical and health food products business recorded a healthy growth of approximately 11.1% compared to the same period in 2021[22]. - The total revenue of Western pharmaceutical and personal care products business delivered a growth of approximately 80.6% over the corresponding period in 2021[24]. - The decline in revenue from property sales in the PRC was attributed to the performance of the Company's 53.37%-owned subsidiary, China Agri-Products Exchange Limited[16]. - CAP managed 11 agricultural produce exchange markets across five provinces in the PRC, generating revenue of approximately HK$303.6 million, down from approximately HK$393.6 million in the same period of 2021[31]. - Revenue from operating agricultural produce exchange markets was approximately HK$195.4 million, compared to approximately HK$203.0 million in the previous year[31]. - Revenue from the sale of properties was approximately HK$108.2 million, a decline from approximately HK$190.6 million in the same period of 2021[31]. Operational Developments - The Group has launched three Chinese specialists centers in Central, Causeway Bay, and Jordan to provide specialized solutions for patients with special medical needs[24]. - The Group plans to introduce nutritious soft meals for the elderly and an advanced disinfectant range under the brand name "Pearl's" in the coming year[24]. - The Group has been actively deploying resources to establish e-commerce channels, including distribution through its own online platform and selected third-party platforms[27]. - The Group expanded its property portfolio by subdividing a property in Mongkok, increasing owned properties from 13 to 14[29][33]. - The Group aims to improve the performance of the existing retail outlet portfolio to counteract the negative impact of the current uncertain business environment[24]. - The Group's efforts in strategic sales and marketing activities have contributed to its market leadership in the mosquito repellent product market in Hong Kong[24]. Financial Position - As of September 30, 2022, the Group's total assets were approximately HK$6,914.2 million, down from approximately HK$7,597.7 million as of March 31, 2022[43]. - The Group's total interest-bearing debts amounted to approximately HK$1,752.8 million as of September 30, 2022, an increase from approximately HK$1,681.2 million as of March 31, 2022[47]. - The current ratio was approximately 1.7 as of September 30, 2022, compared to approximately 1.5 as of March 31, 2022[50]. - The gearing ratio increased to approximately 51.1% as of September 30, 2022, up from approximately 45.3% as of March 31, 2022[50]. - The Group held financial assets at fair value through other comprehensive income of approximately HK$143.7 million and financial assets at fair value through profit or loss of approximately HK$46.0 million as of September 30, 2022[55]. - The Group's total non-current assets decreased to HK$4,315,163,000 as of September 30, 2022, from HK$4,709,007,000 as of March 31, 2022[190]. - Current assets totaled HK$2,599,038,000 as of September 30, 2022, down from HK$2,888,706,000 as of March 31, 2022[190]. - The company's cash and cash equivalents increased to HK$584,962,000 as of September 30, 2022, compared to HK$510,146,000 as of March 31, 2022[190]. Shareholder Information - The CAP Group owns approximately 73.54% of CAP's total issued share capital, amounting to 7,320,095,747 shares[124]. - Mr. Tang Ching Ho holds 67.26% of the company's total issued share capital, with 810,322,940 shares[117]. - The shareholding structure indicates that Mr. Tang and his associates have significant control over the Company through various subsidiaries[142]. - The Company has not granted any rights to acquire shares or debentures to its Directors or chief executives during the reporting period[137]. - The total number of shares held by major shareholders reflects a concentrated ownership structure, with Rich Time and its affiliates holding a substantial portion[139]. Corporate Governance - The company emphasizes maintaining a high standard of corporate governance with a focus on transparency, accountability, integrity, and independence[155]. - The board comprises three executive directors and four independent non-executive directors, ensuring a balance of skills and experience[154]. - The Company has established an Audit Committee to oversee financial reporting, internal controls, and risk management[177]. - The company does not propose to comply with code provision C.2.1 of the Corporate Governance Code for the time being but will continue to review such deviation[154]. Legal Matters - Since 2011, CAP Group has been involved in multiple civil proceedings in the PRC and Hong Kong regarding the Baisazhou Acquisition[82]. - The Hubei Court dismissed Ms. Wang and Tian Jiu's counterclaim for the return of CAP Group's 90% interest in Baisazhou Agricultural in December 2019[90]. - The Supreme People's Court upheld the Hubei Court's decision on 29 March 2021, confirming CAP Group's ownership of Baisazhou Agricultural[88]. - The former director of Baisazhou Agricultural was found guilty of misappropriating funds amounting to RMB 40.0 million and was sentenced to five years in prison[95]. Market Strategy - The Group plans to expand its market share by opening more retail outlets in the PRC, Hong Kong, and Macau, leveraging the development of the Guangdong-Hong Kong-Macau Greater Bay Area[106]. - The Group aims to launch more unique health supplements under the "Madame Pearl's" brand to meet market needs[107]. - The CAP Group will continue to build a nationwide agricultural produce exchange network, leveraging its leading industry position and advanced management systems[108]. - The Group's strategy includes enhancing cross-border e-commerce to reach consumers in the Greater Bay Area and the Asia Pacific Region[107]. - The CAP Group is pursuing an "asset light" strategy to expand operations in the PRC, focusing on partnerships and electronic platform development to leverage technology advancements promoted by the government[112].